ProCE Banner Activity

PARP Inhibition in Prostate Cancer: Optimizing Care for Veterans


Download these slides from interdisciplinary workshops on integrating PARP inhibitor–based regimens into the care of patients with prostate cancer receiving treatment through the Veterans Health Administration.

Released: January 31, 2024



Himisha Beltran

Himisha Beltran, MD

Associate Professor of Medicine
Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts 

Daniel P. Petrylak

Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and of Urology
Director, Prostate and GU Medical Oncology
Yale Cancer Center
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.


Merck & Co., Inc., Rahway, NJ, USA